6/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium Vanderbilt
6/6 六溴环十二烷产前经历和纵向发展 (PRELUDE) 联盟范德比尔特
基本信息
- 批准号:10748148
- 负责人:
- 金额:$ 31.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Administrative SupplementAlcoholsAnxietyBehaviorBehavioralBiologicalBiologyBrainCannabisCaregiversChildChild DevelopmentChild HealthChildhoodCognitionCognitiveCollaborationsCollectionCommunitiesComplexCongenital AbnormalityData CollectionDetectionDevelopmentEducationEpigenetic ProcessEtiologyEvaluationExposure toFamilyFetal GrowthFetal ReductionFetusFundingFutureGenerationsGeneticGoalsHealthHealthcareHeavy MetalsHelping to End Addiction Long-termImmuneIndividualInfant HealthInfrastructureKnowledgeLanguage DelaysLanguage DevelopmentLinkLongitudinal StudiesLow Birth Weight InfantMaternal HealthMediatingMemory impairmentMetabolicNational Institute of Drug AbuseNeonatal Abstinence SyndromeOpioidOutcomeParentsParticipantPathogenicityPlacentaPoliciesPredispositionPregnancyPregnant WomenPremature BirthPrenatal carePreventionPrevention strategyProcessProteinsProtocols documentationPsychopathologyResearch SupportResourcesRiskSamplingSignaling ProteinSiteSpecimenTissue BanksTissuesTobaccoTraumaUmbilical Cord BloodUmbilical cord structureUnited StatesUnited States National Institutes of Healthadverse outcomealcohol consumption during pregnancyemotion regulationfetalfetal opioid exposurefetal substance exposurein uteroinattentioninnovationinterestlongitudinal, prospective studymRNA Expressionmaternal opioid useneonatal healthneurodevelopmentneuroimagingnutritionopioid useopioid use disorderopioid use in pregnancypatients who use opioidspolysubstance usepregnantprenatalprenatal experienceprotocol developmentracismresponsesocialsubstance usesuccesstoxicant
项目摘要
PROJECT SUMMARY/ABSTRACT
Opioid use during pregnancy is widespread and associated with adverse outcomes for the pregnant individual
and the developing child. Prenatal opioid exposure is associated with a wide range of negative fetal and child
outcomes including reduced fetal growth, premature birth, lower birth weight, congenital defects, increased
neonatal healthcare, and heightened risk for later behavioral (e.g., anxiety, inattention), cognitive (e.g., memory
deficits, delayed language acquisition), and metabolic problems. Despite opioid use being linked to adverse
maternal, fetal, and child outcomes, the mechanisms through which these arise and the potential
consequences of prenatal opioid exposure for child health and development (e.g., brain and behavior) remain
largely unexplored. This lack of etiologic knowledge has contributed to stagnant treatment, prevention, and
mitigation efforts leaving individuals and families susceptible to reverberating adverse outcomes.
The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early
child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics,
epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g.,
racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women
and their children from pregnancy to mid-childhood. A major goal of the HBCD study is to increase
understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal
substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or
tobacco during pregnancy and 12% of the total sample will be using opioids) and offers a unique opportunity to
inform our understanding of how the adverse consequences associated with opioid use during pregnancy
arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the
US, the core protocol does not include the collection of delivery biospecimens. This Administrative Supplement
in response to the NIDA/ORWH Administrative Supplement Notice of Special Interests: HEAL Initiative:
Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage the HEALthy Brain and Child
Development (HBCD) by expanding the biospecimen collection of the Core HBCD Protocol to include delivery
specimens (placenta, cord tissue, cord blood). Delivery samples will be collected from a representative sample
of HBCD Study participants across up to 14 sites (and over 2,000 participants across HBCD sites submitting
applications in response to this NOSI). This will provide an unprecedented resource generating opportunity for
a larger scientific community to comprehensively evaluate pathophysiological mechanisms that mediate the
connection between opioid and polysubstance use during pregnancy and adverse neonatal, infant, and/or
maternal health outcomes and, in turn, inform innovative preventive strategies.
项目总结/摘要
妊娠期间使用阿片类药物很普遍,并与妊娠个体的不良结局相关
和发育中的孩子。产前阿片类药物暴露与广泛的阴性胎儿和儿童相关
结果包括胎儿生长减慢、早产、出生体重降低、先天性缺陷、
新生儿保健,以及后期行为的风险增加(例如,焦虑,注意力不集中),认知(例如,存储器
缺陷,语言习得延迟)和代谢问题。尽管阿片类药物的使用与不良反应有关,
孕产妇,胎儿和儿童的结果,通过这些产生的机制和潜在的
产前阿片类药物暴露对儿童健康和发育的影响(例如,大脑和行为)仍然存在
大部分未开发。缺乏病因学知识导致了治疗、预防和治疗的停滞,
缓解努力使个人和家庭容易受到负面影响。
健康大脑和儿童发育(HBCD)研究是一项25个研究中心的纵向前瞻性研究,
在美国的儿童发展,将评估广泛的生物(例如,神经影像学,遗传学,
表观遗传学),行为(例如,认知和情绪调节),经验的(例如,创伤),社会(例如,
种族主义)和健康(例如,精神病理学)因素在约7,500名全国代表性孕妇中进行了研究
和他们的孩子从怀孕到童年中期。六溴环十二烷研究的一个主要目标是增加
了解产前物质暴露的潜在后果。它将丰富产妇
怀孕期间使用的物质(即,约25%的样本将使用阿片类药物、大麻、酒精和/或
怀孕期间吸烟和总样本的12%将使用阿片类药物),并提供了一个独特的机会,
告知我们对妊娠期间使用阿片类药物相关不良后果的理解
起来。虽然六溴环十二烷将是世界上最大的早期大脑和儿童发育结果长期研究,
在美国,核心方案不包括交付生物标本的采集。本行政补充文件
回应NIDA/ORWH行政补充特别利益通知:HEAL倡议:
妊娠期生物标本采集(NOT-DA-23-005)建议利用健康的大脑和儿童
通过扩大六溴环十二烷核心议定书的生物标本收集以包括交付,
样本(胎盘、脐带组织、脐带血)。将从代表性样品中收集交付样品
六溴环十二烷研究参与者在多达14个研究中心的人数(以及六溴环十二烷研究中心的2,000多名参与者提交了
(针对此NOSI的应用)。这将提供前所未有的资源产生机会,
一个更大的科学界,以全面评估病理生理机制,介导
妊娠期间使用阿片类药物和多种物质与新生儿、婴儿和/或
孕产妇保健成果,并反过来为创新的预防战略提供信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laurie E Cutting其他文献
Laurie E Cutting的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laurie E Cutting', 18)}}的其他基金
Neural Correlates of Discourse Processing in Adolescents
青少年话语处理的神经相关性
- 批准号:
10687822 - 财政年份:2022
- 资助金额:
$ 31.74万 - 项目类别:
Neurobiology and Treatment of Reading Disability in NF1
神经生物学和 NF1 阅读障碍的治疗
- 批准号:
10628742 - 财政年份:2022
- 资助金额:
$ 31.74万 - 项目类别:
6/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium Vanderbilt
6/6 六溴环十二烷产前经历和纵向发展 (PRELUDE) 联盟范德比尔特
- 批准号:
10494153 - 财政年份:2021
- 资助金额:
$ 31.74万 - 项目类别:
6/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium Vanderbilt
6/6 六溴环十二烷产前经历和纵向发展 (PRELUDE) 联盟范德比尔特
- 批准号:
10661775 - 财政年份:2021
- 资助金额:
$ 31.74万 - 项目类别:
Early Academic Achievement and Intervention Response: Role of Executive Function
早期学业成就和干预反应:执行功能的作用
- 批准号:
10329261 - 财政年份:2021
- 资助金额:
$ 31.74万 - 项目类别:
6/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium Vanderbilt
6/6 六溴环十二烷产前经历和纵向发展 (PRELUDE) 联盟范德比尔特
- 批准号:
10380490 - 财政年份:2021
- 资助金额:
$ 31.74万 - 项目类别:
相似海外基金
Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
- 批准号:
2304861 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Continuing Grant
STTR Phase I: Development of Modular Reactors to Convert Methane to Alcohols at Low Temperatures
STTR 第一阶段:开发在低温下将甲烷转化为醇的模块化反应器
- 批准号:
2151256 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Standard Grant
Development of amine-dehydrogenase and lyase biocatalysts for the sustainable manufacturing of unnatural chiral amino acids and amino alcohols
开发胺脱氢酶和裂解酶生物催化剂,用于可持续生产非天然手性氨基酸和氨基醇
- 批准号:
2870226 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Studentship
Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
- 批准号:
2304860 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Continuing Grant
Postdoctoral Fellowship: MPS-Ascend: Development of Selective Reaction Schemes for Photoactivation of Alcohols
博士后奖学金:MPS-Ascend:醇光活化选择性反应方案的开发
- 批准号:
2316541 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Fellowship Award
Development of phosphorylation of alcohols in protein based on the structural modification of phosphoenolpyruvate
基于磷酸烯醇丙酮酸结构修饰的蛋白质醇磷酸化研究进展
- 批准号:
22KJ1152 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Nickel Cross-Coupling Cascades with α-Heteroatom Radicals to Prepare Sterically Hindered Alcohols and Amines
镍与α-杂原子自由基交叉偶联级联制备位阻醇和胺
- 批准号:
10604535 - 财政年份:2023
- 资助金额:
$ 31.74万 - 项目类别:
Towards a better understanding of the effect of the pentafluorosulfanyl group on the lipophilicity and acid/base properties of alcohols and amines
更好地了解五氟硫基对醇和胺的亲脂性和酸/碱性质的影响
- 批准号:
571856-2021 - 财政年份:2022
- 资助金额:
$ 31.74万 - 项目类别:
Alliance Grants
Pd-Catalyzed C(sp3)-H Functionalizations Directed by Free Alcohols and Boc-Protected Amines
由游离醇和 Boc 保护的胺引导的 Pd 催化 C(sp3)-H 官能化
- 批准号:
10606508 - 财政年份:2022
- 资助金额:
$ 31.74万 - 项目类别:
MPS-Ascend: Nickel/Photoredox-Catalyzed C(sp3)–C(sp3) Cross-Coupling Between Alkyl Halides and Activated Alcohols
MPS-Ascend:镍/光氧化还原催化的 C(sp3)→C(sp3) 烷基卤化物和活化醇之间的交叉偶联
- 批准号:
2213210 - 财政年份:2022
- 资助金额:
$ 31.74万 - 项目类别:
Fellowship Award